Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine PK and Safety in Pediatric ASD
NCT04382885Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of cariprazine in Autism Spectrum Disorder (ASD) (4 cohorts), sponsored by AbbVie Inc. Primary endpoints: Incidence of Adverse Events, Incidence of Serious Adverse Events and 15 more. Started Jun 2020; status: completed.
02
Drugs
cariprazine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04382885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382885.